Literature DB >> 12657363

Apoptosis and Parkinson's disease.

Nirit Lev1, Eldad Melamed, Daniel Offen.   

Abstract

Parkinson's disease (PD) is a severe and progressive neurodegenerative disease. It is the second most common neurodegenerative disease, after Alzheimer's disease. It is caused by the selective loss of the dopaminergic neurons in the substantia nigra (SN) pars compacta. Although subject to intensive research, the etiology of PD is still enigmatic and treatment is basically symptomatic. Many factors are thought to operate in the mechanism of cell death of the nigrostriatal dopaminergic neurons in PD. In recent years, evidence for the role of apoptotic cell death in PD arises from morphological, as well as molecular, studies in cell cultures, animal models for PD, as well as human studies on postmortem brains from PD patients. These studies indicate that apoptosis takes place in PD and that there is a proapoptotic environment in the nigrostriatal region of parkinsonian patients. It is of utmost importance to conclusively determine the mode of cell death in PD because new "antiapoptotic" compounds may offer a means of protecting neurons from cell death and of slowing the rate of neurodegeneration and disease progression.

Entities:  

Mesh:

Year:  2003        PMID: 12657363     DOI: 10.1016/S0278-5846(03)00019-8

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  37 in total

1.  Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors.

Authors:  Wenjing Xu; Judy P Q Zhu; Jesus A Angulo
Journal:  Synapse       Date:  2005-11       Impact factor: 2.562

2.  Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects.

Authors:  Mariama S Azmy; Esther T Menze; Reem N El-Naga; Mariane G Tadros
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

3.  Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease.

Authors:  Wu-Fu Chen; Chiranjib Chakraborty; Chun-Sung Sung; Chien-Wei Feng; Yen-Hsuan Jean; Yen-You Lin; Han-Chun Hung; Tzu-Yi Huang; Shi-Ying Huang; Thung-Ming Su; Ping-Jyun Sung; Jyh-Horng Sheu; Zhi-Hong Wen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-27       Impact factor: 3.000

4.  The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss.

Authors:  Elizabeth M Kline; Laura M Butkovich; Joshua M Bradner; Jianjun Chang; Harris Gelbard; Val Goodfellow; W Michael Caudle; Malú G Tansey
Journal:  Exp Neurol       Date:  2019-05-08       Impact factor: 5.330

Review 5.  Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview.

Authors:  Khurshid Ahmad; Mohammad Hassan Baig; Gohar Mushtaq; Mohammad Amjad Kamal; Nigel H Greig; Inho Choi
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

6.  Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease.

Authors:  G Watfa; C Dragonas; T Brosche; R Dittrich; C C Sieber; C Alecu; A Benetos; R Nzietchueng
Journal:  J Nutr Health Aging       Date:  2011-04       Impact factor: 4.075

Review 7.  Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders.

Authors:  Mark D Berry
Journal:  J Psychiatry Neurosci       Date:  2004-09       Impact factor: 6.186

8.  Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat.

Authors:  Siamak Afshin-Majd; Mohsen Khalili; Mehrdad Roghani; Narges Mehranmehr; Tourandokht Baluchnejadmojarad
Journal:  Mol Neurobiol       Date:  2014-06-18       Impact factor: 5.590

9.  Association between Anemia and Risk of Parkinson Disease.

Authors:  Yao-Chin Wang; Abel Po-Hao Huang; Sheng-Po Yuan; Chu-Ya Huang; Chieh-Chen Wu; Tahmina Nasrin Poly; Suleman Atique; Woon-Man Kung
Journal:  Behav Neurol       Date:  2021-07-07       Impact factor: 3.342

10.  Protective effects of baicalin in a Caenorhabditis elegans model of Parkinson's disease.

Authors:  Jing Ma; Ranran Wang; Ting Chen; Shaowei Jiang; Ajing Xu
Journal:  Toxicol Res (Camb)       Date:  2021-04-26       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.